Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2012

View Archived Issues

Suven Life Sciences synthesizes new cognition-enhancing drug candidates

Cell Therapeutics to acquire JAK2 inhibitor from S*Bio

Novel antibody drug fights cancer via new mode of action

U.S. study uncovers new candidate glioma biomarker

Spherix presents results from studies in patients with cardiovascular disease

Proof of concept established for Presidio drug

AT-001 set to enter phase I study in Russia

GSK launches solution for pneumocystis pneumonia in Japan

Two new anticancer therapies presented

RedHill reports RHB-102 bioequivalence data

Advaxis describes two new cancer immunotherapies

Human Genome Sciences receives acquisition offer

Xencor receives milestone payment from CSL

CrystalGenomics reports on phase IIb CG-100649 trial

First patient dosed in new phase I AZD-2820 trial

Michael J. Fox Foundation to sponsor study of Sanofi compound

Senju Pharmaceutical plans new release of ophthalmic solution

Novartis amends U.S. labeling of aliskiren drugs, withdraws Valturna

Pharmaxis product approved in E.U. for cystic fibrosis

Novel orexin OX1 and OX2 receptor antagonists patented

Novel candidate cancer therapies developed by Sanofi

Collaboration yields novel brucellosis vaccines

New antibacterial vaccines patented

Aragon Pharmaceuticals discloses new estrogen receptor modulators

Novel antivirals divulged by Gilead Sciences

Cytokinetics ALS drug candidate gets FDA fast track status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...